For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
According to our (Global Info Research) latest study, the global Antisense & RNAi Therapeutics market size was valued at USD 986.3 million in 2022 and is forecast to a readjusted size of USD 1303.9 million by 2029 with a CAGR of 4.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.
This report is a detailed and comprehensive analysis for global Antisense & RNAi Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Antisense & RNAi Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Antisense & RNAi Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Antisense & RNAi Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Antisense & RNAi Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antisense & RNAi Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antisense & RNAi Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Arbutus Biopharma Ltd. and Silence Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Antisense & RNAi Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- RNA Interference
- SiRNA
- MiRNA
- Antisense RNA
Market segment by Application
- Oncology
- Cardiovascular
- Renal
- Neurodegenerative
- Respiratory
- Genetic
- Infectious Diseases
Market segment by players, this report covers
- Glaxo Smith Kline
- Sanofi Aventis / Genzyme
- Isis Pharmaceuticals/ Ionis Pharmaceuticals
- Arbutus Biopharma Ltd.
- Silence Therapeutics
- Bio-Path Holdings Inc.
- Calando Pharmaceuticals
- ICo Therapeutics
- Quark Pharmaceuticals
- Rexhan Pharmaceuticals
- Biomarin/Prosensa
- Regulus Therapeutics
- Rxi Pharmaceuticals
- Silenseed
- Dicerna Pharmaceuticals
- Sirnaomics Inc.
Market segment by regions, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Antisense & RNAi Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antisense & RNAi Therapeutics, with revenue, gross margin and global market share of Antisense & RNAi Therapeutics from 2018 to 2023.
Chapter 3, the Antisense & RNAi Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antisense & RNAi Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense & RNAi Therapeutics.
Chapter 13, to describe Antisense & RNAi Therapeutics research findings and conclusion.